Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition

被引：27
|
作者：
Hude, Ida [1 ,2 ]
Sasse, Stephanie [1 ]
Broeckelmann, Paul J. [1 ]
von Tresckow, Bastian [1 ]
Momotow, Jesko [1 ]
Engert, Andreas [1 ]
Borchmann, Sven [1 ]
机构：
[1] Univ Hosp Cologne, GHSG, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Ctr Zagreb, Div Haematol, Dept Internal Med, Zagreb, Croatia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷 / 06期
关键词：
Hodgkin lymphoma; immune checkpoint inhibition; biomarkers; eosinophils; immunotherapy; BRENTUXIMAB VEDOTIN; NIVOLUMAB; BLOCKADE; FAILURE;
D O I：
10.1111/bjh.14705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：837 / 840
页数：4
相关论文
共 50 条
  • [21] Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin's Lymphoma
    Tan, Grace Fangmin
    Goh, Siting
    Chang, Esther Wei Yin
    Tan, Ya Hwee
    Chiang, Jianbang
    Yang, Valerie Shiwen
    Poon, Eileen Yi Ling
    Somasundaram, Nagavalli
    Rashid, Mohamad Farid Bin Harunal
    Tao, Miriam
    Lim, Soon Thye
    Ong, Choon Kiat
    Chan, Jason Yongsheng
    HEMATOLOGY REPORTS, 2023, 15 (01) : 108 - 118
  • [22] Dominant negative PD1 armored CART cells induce remission in relapsed or refractory Non-Hodgkin Lymphoma (NHL) patients
    Pu, Cheng Fei
    Xiao, Lei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [23] Dominant Negative PD1 Armored CART Cells Induce Remission in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients
    Yuan, Yan
    Huang, Liansheng
    Su, Yang
    Pu, Chengfei
    Ding, Tianling
    Xiao, Xibin
    Jin, Lina
    Cao, Zhiyuan
    Wu, Ting
    Chen, Tong
    Ding, Luying
    Zhang, Xiaohong
    Lan, Haifeng
    Wu, Zhao
    Xiao, Lei
    MOLECULAR THERAPY, 2020, 28 (04) : 334 - 334
  • [24] PROGRESSION-FREE SURVIVAL AS A PRIMARY OUTCOME MEASURE TO COMPARE CONSOLIDATIVE STRATEGIES IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA
    Bonm, Alipi
    Gibson, Alec
    Holmberg, Leona
    Mielcarec, Marco
    McGranahan, Tresa
    Taylor, Lynne
    Graber, Jerome
    NEURO-ONCOLOGY, 2020, 22 : 142 - 142
  • [25] An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma
    Wight, Joel C.
    Hawkes, Eliza A.
    Berlangieri, Salvatore U.
    Khor, Richard
    Grigg, Andrew P.
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2749 - 2751
  • [26] Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials
    Broeckelmann, Paul J.
    Mueller, Horst
    Gillessen, Sarah
    Jacob, Anne Sophie
    Momotow, Jesko
    Damaschin, Carla
    Ferdinandus, Justin
    Yang, Xiaoqin
    Fuchs, Michael
    Kobe, Carsten
    Eich, Hans Theodor
    Engert, Andreas
    Borchmann, Peter
    von Tresckow, Bastian
    BLOOD, 2023, 142
  • [27] TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin
    Chen, Robert W.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (02) : 10 - 12
  • [28] Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
    Drees, Esther E. E.
    Jauw, Yvonne W. S.
    van Dijk, Erik
    Borchmann, Sven
    Verkuijlen, Sandra A. W. M.
    Stathi, Phylicia
    Groenewegen, Nils J.
    Hijmering, Nathalie J.
    Berry, Daniella R. A. I.
    Meershoek, Eric J.
    Hoogmoed, Danielle
    Kwakman, Anne
    Molenaar, Tessa J.
    Pegtel, Dirk M.
    Ylstra, Bauke
    de Jong, Daphne
    Zijlstra, Josee M.
    Roemer, Margaretha G. M.
    HEMASPHERE, 2022, 6 (07):
  • [29] Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
    Yang, Tung-Lung
    Lin, Chin
    Ho, Ching-Liang
    Huang, Tzu-Chuan
    Wu, Yi-Ying
    Jhou, Hong-Jie
    Chen, Po-Huang
    Lee, Cho-Hao
    LIFE-BASEL, 2023, 13 (12):
  • [30] Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
    Avet-Loiseau, Herve
    Bahlis, Nizar J.
    Chng, Wee-Joo
    Masszi, Tamas
    Viterbo, Luisa
    Pour, Ludek
    Ganly, Peter
    Palumbo, Antonio
    Cavo, Michele
    Langer, Christian
    Pluta, Andrzej
    Nagler, Arnon
    Kumar, Shaji
    Ben-Yehuda, Dina
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Berg, Deborah
    Lin, Jianchang
    van de Velde, Helgi
    Esseltine, Dixie-Lee
    di Bacco, Alessandra
    Moreau, Philippe
    Richardson, Paul G.
    BLOOD, 2017, 130 (24) : 2610 - 2618
12345